AbbVie Sets Out Expectations For 2024 Humira Competition
Offers Overview Of Anticipated Impact From Adalimumab Biosimilars In The Year Ahead
As AbbVie reported fourth-quarter and full-year results for 2023, the firm set out its expectations for adalimumab biosimilar competition to Humira in the year ahead, particularly in the US.
